Literature DB >> 33480190

External beam radiotherapy for prostate cancer: What are the current research trends and hotspots?

Rui Li1,2, Xia Liu1,2, Bo Yang1,2, Jie Qiu1,2.   

Abstract

BACKGROUND: The external beam radiotherapy (EBRT) applied for prostate cancer (PCa) has been one of the most important and hottest research fields over recent decades. This study aimed to explore the research hotspots of EBRT in PCa and help the researchers have a clear and intuitive reference basis for later researches.
METHODS: The literature scientometric analysis related to "EBRT applied for PCa" was conducted via the Web of Science Core Collection from 2010 to 2019. The Microsoft Office Excel 2019 and CiteSpace V. 5.7.R1 software were introduced for visualizing and analyzing the data.
RESULTS: A total of 7860 relevant papers were extracted and downloaded. A total of 7828 papers were extracted and analyzed after data cleansing by CiteSpace. The tendency of published papers was comprehensively increasing from 2010 to 2019. Among all 73 countries/regions, USA published the most papers, accounting for 39%, which was the most active contributor with most publications. Australia (Centrality: 0.18), England (Centrality: 0.12) were cooperating most cohesively with other countries. Univ Toronto was the most productive institute (229), while Harvard Univ (Centrality: 0.67) had extensive collaborations with other institutes. The International journal of Radiation Oncology Biology Physics had the largest number of publications and the highest number of co-citations. Briganti A had the largest volume of publications. D'Amico AV had the highest number of co-citations. Four latest and largest clusters were identified as oligometastases, salvage therapy (SRT), prostate-specific membrane antigen (PSMA), and hypofractionation. Thirteen references became strongest burst citations lasting until 2019. The studies of "oligometastases," "SRT," "PSMA," "hypofractionation," "postoperative radiotherapy," and "dose and fraction regimen changes" were prevailing in the recent years.
CONCLUSION: The "oligometastases," "SRT," "PSMA," "hypofractionation," "postoperative radiotherapy," and "dose and fraction regimen changes" may be the state-of-art research frontiers, and related studies will advance in this field over time.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  EBRT; global trends; prostate cancer; scientometric analysis; visualization analysis

Mesh:

Year:  2021        PMID: 33480190      PMCID: PMC7877352          DOI: 10.1002/cam4.3700

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  52 in total

1.  68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.

Authors:  Wolfgang Peter Fendler; Jeremie Calais; Martin Allen-Auerbach; Christina Bluemel; Nina Eberhardt; Louise Emmett; Pawan Gupta; Markus Hartenbach; Thomas A Hope; Shozo Okamoto; Christian Helmut Pfob; Thorsten D Pöppel; Christoph Rischpler; Sarah Schwarzenböck; Vanessa Stebner; Marcus Unterrainer; Helle D Zacho; Tobias Maurer; Christian Gratzke; Alexander Crispin; Johannes Czernin; Ken Herrmann; Matthias Eiber
Journal:  J Nucl Med       Date:  2017-04-13       Impact factor: 10.057

Review 2.  Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction.

Authors:  W Robert Lee
Journal:  Future Oncol       Date:  2007-12       Impact factor: 3.404

3.  A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.

Authors:  Michael McCarthy; Roslyn Francis; Colin Tang; Joanne Watts; Andrew Campbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-16       Impact factor: 7.038

4.  68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Authors:  Jeremie Calais; Johannes Czernin; Minsong Cao; Amar U Kishan; John V Hegde; Narek Shaverdian; Kiri Sandler; Fang-I Chu; Chris R King; Michael L Steinberg; Isabel Rauscher; Nina-Sophie Schmidt-Hegemann; Thorsten Poeppel; Philipp Hetkamp; Francesco Ceci; Ken Herrmann; Wolfgang P Fendler; Matthias Eiber; Nicholas G Nickols
Journal:  J Nucl Med       Date:  2017-11-09       Impact factor: 10.057

5.  Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

Authors:  Piet Ost; Barbara Alicja Jereczek-Fossa; Nicholas Van As; Thomas Zilli; Alexander Muacevic; Kenneth Olivier; Daniel Henderson; Franco Casamassima; Roberto Orecchia; Alessia Surgo; Lindsay Brown; Alison Tree; Raymond Miralbell; Gert De Meerleer
Journal:  Eur Urol       Date:  2015-07-16       Impact factor: 20.096

6.  Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.

Authors:  Ian M Thompson; Richard K Valicenti; Peter Albertsen; Brian J Davis; S Larry Goldenberg; Carol Hahn; Eric Klein; Jeff Michalski; Mack Roach; Oliver Sartor; J Stuart Wolf; Martha M Faraday
Journal:  J Urol       Date:  2013-05-21       Impact factor: 7.450

7.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

8.  Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

Authors:  Michael J Zelefsky; Marisa Kollmeier; Brett Cox; Anthony Fidaleo; Dahlia Sperling; Xin Pei; Brett Carver; Jonathan Coleman; Michael Lovelock; Margie Hunt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

9.  Long-term functional outcomes after treatment for localized prostate cancer.

Authors:  Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson
Journal:  N Engl J Med       Date:  2013-01-31       Impact factor: 91.245

10.  The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.

Authors:  John F Ward; Michael L Blute; Jeffrey Slezak; Erik J Bergstralh; Horst Zincke
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

View more
  2 in total

1.  Detecting the Research Trends and Hot Spots in External Irradiation Therapy for Rectal Cancer.

Authors:  Qian Bi; Zheng Miao; Jing Shen; Hao Wang; Kai Kang; Junjie Du; Fuquan Zhang; Shaoping Fan
Journal:  J Cancer       Date:  2022-04-04       Impact factor: 4.478

2.  Mapping Intellectual Structure for the Long Non-Coding RNA in Hepatocellular Carcinoma Development Research.

Authors:  Zhifeng Lin; Xiaohui Ji; Nana Tian; Yu Gan; Li Ke
Journal:  Front Genet       Date:  2022-01-03       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.